Skip to main content

Advertisement

SpringerLink
Log in

The four steps in the prevention of human papillomavirus-associated neoplasia

Considerations for preventive measures, screening, disease impact, and potential overtreatments in HPV-related pathology

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

There is no cure currently available for HPV infections, although ablative and excisional treatments of some dysplasias often result in a clinical and virological cure. Effective control measures of HPV-associated cancers rely on the prevention at four different levels. Apart from sexual abstinence, primary prevention is realized through vaccines targeting the most frequent HPV types: negative attitudes towards HPV vaccination and high costs are the main obstacles. The aim of secondary prevention is to detect precancerous changes before they develop into invasive cancer, while tertiary prevention involves actual treatment of high-grade lesions: in many countries routine screening with cytology is being challenged with HPV DNA testing. Quaternary prevention comprehends those actions adopted to mitigate or avoid unnecessary or excessive medical interventions, and may well be addressed in avoiding treatments for low-grade intraepithelial neoplasia. Though some gynecologists commonly recommend treatment for low-grade disease and women tend to prefer active management if not properly informed, harms arising from unnecessary treatments, increased costs, work overload for second-level health services, and induced psychosocial distress are causing on-going problems. Prevention efforts of genital HPV-associated cancers should concentrate in: (1) enhancing primary prevention through vaccination of all eligible subjects, (2) achieving high levels of adherence to routine screening programs, (3) treating precancerous lesions, and (4) monitoring current guidelines recommendations to avoid overtreatments. Novel research projects should be designed to study the delicate mechanisms of immune response to HPV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H (2004) Classification of papillomaviruses. Virology 324:17–27

    PubMed  Google Scholar 

  2. Steben M, Duarte-Franco E (2007) Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107(2 Suppl 1):S2–S5

    PubMed  CAS  Google Scholar 

  3. Ganguly N, Parihar SP (2009) Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 34(1):113–123

    PubMed  CAS  Google Scholar 

  4. Shew M, Ermel A, Weaver B, Denski C, Tong Y, Tu W, Fortenberry JD, Qadadri B, Brown D (2011) HPV detection from adolescent women with prolonged follow-up. 27th International papillomavirus conference. Berlin, Epidemiology/Public Health Abstract Book; 08.07:160p

  5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189(1):12–19

    PubMed  CAS  Google Scholar 

  6. Zur Hausen H (2009) Papillomaviruses in the causation of human cancers—a brief historical account. Virology 384(2):260–265

    PubMed  CAS  Google Scholar 

  7. Schiffman M, Rodriguez AC, Chen Z, Wacholder S, Herrero R, Hildesheim A, Desalle R, Befano B, Yu K, Safaeian M, Sherman ME, Morales J et al (2010) A population-based prospective study of carcinogenic human papillomavirus (HPV) variant lineages, viral persistence, and cervical neoplasia. Cancer Res 70(8):3159–3169

    PubMed  CAS  Google Scholar 

  8. Widdice LE (2012) Human papillomavirus disease in adolescents: management and prevention. Adolesc Med State Art Rev 23(1):192–206

    PubMed  Google Scholar 

  9. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7:453–459

    PubMed  Google Scholar 

  10. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE (2011) Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003–2006. J Infect Dis 204(4):566–573

    PubMed  Google Scholar 

  11. Kjaer SK, Tran TN, Sparen P, Tryggvadottir L, Munk C, Dasbach E, Liaw KL, Nygård J, Nygård M (2007) The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 196(10):1447–1454

    PubMed  Google Scholar 

  12. Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL et al (2012) EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 131(9):1969–1982

    PubMed  CAS  Google Scholar 

  13. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, Chimera J, Reingold A, Manos MM (1991) Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265(4):472–477

    PubMed  CAS  Google Scholar 

  14. Rousseau MC, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL (2001) Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184(12):1508–1517

    PubMed  CAS  Google Scholar 

  15. Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Désy M, Rohan TE (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180(5):1415–1423

    PubMed  CAS  Google Scholar 

  16. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M et al (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92(6):464–474

    PubMed  CAS  Google Scholar 

  17. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370(9590):890–907

    PubMed  CAS  Google Scholar 

  18. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ (2004) Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111(2):278–285

    PubMed  Google Scholar 

  19. Maglennon GA, McIntosh P, Doorbar J (2011) Persistence of viral DNA in the epithelial basal layer suggests a model for papillomavirus latency following immune regression. Virology 414(2):153–163

    PubMed  CAS  Google Scholar 

  20. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE (2012) Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res 72(23):6183–6190

    PubMed  CAS  Google Scholar 

  21. Ault KA (2006) Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006(Suppl):40470

    PubMed  Google Scholar 

  22. Manhart LE, Koutsky LA (2002) Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29(11):725–735

    PubMed  Google Scholar 

  23. Fehrmann F, Laimins LA (2003) Human papillomaviruses: targeting differentiating epithelial cells for malignant transformation. Oncogene 22(33):5201–5207

    PubMed  CAS  Google Scholar 

  24. Zur Hausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Phys 111:1–7

    Google Scholar 

  25. Zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690–698

    PubMed  CAS  Google Scholar 

  26. Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci Lond 110(5):525–541

    PubMed  CAS  Google Scholar 

  27. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151:1158–1171

    PubMed  CAS  Google Scholar 

  28. Koutsky LA, Galloway DA, Holmes KK (1988) Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10:122–163

    PubMed  CAS  Google Scholar 

  29. Dunne EF, Unger ER, Sternberg M, Mc Quillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 287(8):813–819

    Google Scholar 

  30. Winer RL, Feng Q, Hughes JP, O’Reilly S, Kiviat NB, Koutsky LA (2008) Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis 197(2):279–282

    PubMed  Google Scholar 

  31. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186:1396–1402

    PubMed  Google Scholar 

  32. Gravitt PE (2011) The known unknowns of HPV natural history. J Clin Invest 121(12):4593–4599

    PubMed  CAS  Google Scholar 

  33. Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M (2008) An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL triage study (ALTS). Obstet Gynecol 111(4):847–856

    PubMed  Google Scholar 

  34. Liverani CA, Ciavattini A, Monti E, Puglia D, Mangano S, Di Giuseppe J, Zizzi A, Goteri G, Bolis G (2012) High risk HPV DNA subtypes and E6/E7 mRNA expression in a cohort of colposcopy patients from Northern Italy with high-grade histologically verified cervical lesions. Am J Transl Res 4(4):452–457

    CAS  Google Scholar 

  35. Calhoun ES, McGovern RM, Janney CA, Cerhan JR, Iturria SJ, Smith DI, Gostout BS, Persing DH (2002) Host genetic polymorphism analysis in cervical Cancer. Clin Chem 48(8):1218–1224

    PubMed  CAS  Google Scholar 

  36. Oldstone MBA (2009) Anatomy of viral persistence. PLoS Pathog 5(7):e1000523

    PubMed  Google Scholar 

  37. Füle T, Máthé M, Suba Z, Csapó Z, Szarvas T, Tátrai P, Paku S, Kovalszky I (2006) The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology 348(2):289–296

    PubMed  Google Scholar 

  38. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ (2002) ASCCP-sponsored consensus conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287(16):2120–2129

    PubMed  Google Scholar 

  39. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Young N, Forum group members; bethesda 2001 workshop (2002) The 2001 bethesda system: terminology for reporting results of cervical cytology. JAMA 287:2114–2119

    PubMed  Google Scholar 

  40. Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody (2004) Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the college of American pathologists interlaboratory comparison program in cervicovaginal cytology. Arch Pathol Lab Med 128(11):1224–1229

    PubMed  Google Scholar 

  41. Munk AC, Kruse AJ, van Diermen B, Janssen EA, Skaland I, Gudlaugsson E, Nilsen ST, Baak JP (2007) Cervical intraepithelial grade 3 lesions can regress. APMIS 115(12):1409–1414

    PubMed  Google Scholar 

  42. Holowaty P, Miller AB, Rohan T, To T (1999) Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 91(3):252–258

    PubMed  CAS  Google Scholar 

  43. Barbisan G, Pérez LO, Contreras A, Golijow CD (2012) TNF-α and IL-10 promoter polymorphisms, HPV infection, and cervical cancer risk. Tumour Biol 33(5):1549–1556

    PubMed  CAS  Google Scholar 

  44. Frey MK, Gupta D (2011) Evaluation of women with atypical glandular cells on cervical cytology. Gynecol Oncol 36(9):23–29

    Google Scholar 

  45. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D (2007) 2006 ASCCP-sponsored consensus conference2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 11(4):201–222

    PubMed  Google Scholar 

  46. Massad LS (2008) Assessing new technologies for cervical cancer screening: beyond sensitivity. J Low Genit Tract Dis 12:311–315

    PubMed  Google Scholar 

  47. Malila N, Leinonen M, Kotaniemi-Talonen L, Laurila P, Tarkkanen J, Hakama M (2013) The HPV test has similar sensitivity but more overdiagnosis than the Pap test—A randomised health services study on cervical cancer screening in Finland. Int J Cancer 132(9):2141–2147

    PubMed  CAS  Google Scholar 

  48. Moyer VA (2012) On behalf of the U.S. preventive services task force. Screening for cervical cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 156(12):880–891

    PubMed  Google Scholar 

  49. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FAR, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER (2012) American cancer society, American society for colposcopy and cervical pathology, and American society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62(3):147–172

    PubMed  Google Scholar 

  50. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, For the 2012 ASCCP Consensus Guidelines Conference (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 121(4):829–846

    PubMed  Google Scholar 

  51. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Cuzick J, and the Athena HPV Study Group (2013) Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208:184.e1–184.e11

    Google Scholar 

  52. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA (2009) HPV screening for cervical cancer in rural India. N Eng J Med 360(14):1385–1394

    CAS  Google Scholar 

  53. Rebolj M, Lynge E (2010) Has cytology become obsolete as a primary test in screening for cervical cancer? J Med Screen 17:1–2

    PubMed  Google Scholar 

  54. Kitchener HC, Altamonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, Gilham C, Baysson H, Roberts C, Dowie R, Desai M, Mather J, Bailey A, Turner A, Moss S, Peto J (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10(7):672–682

    PubMed  Google Scholar 

  55. Patanwala IY, Bauer HM, Miyamoto J, Park IU, Huchko MJ, Smith-McCune KK (2013) A systematic review of randomized trials assessing human papillomavirus testing in cervical cancer screening. Am J Obstet Gynecol 208(5):343–353

    PubMed  Google Scholar 

  56. Lee JW, Berkowitz Z, Saraiya M (2011) Low-risk human papillomavirus testing and other nonrecommended human papillomavirus testing practices among U.S. health care providers. Obstet Gynecol 118(1):4–13

    PubMed  Google Scholar 

  57. Castle PE (2011) Abuses in human papillomavirus DNA Testing. Obstet Gynecol 118(1):1–3

    PubMed  Google Scholar 

  58. Frederiksen ME, Lynge E, Rebolj M (2012) What women want? Women’s preferences for the management of low-grade abnormal cervical screening tests: a systematic review. BJOG 119:7–19

    PubMed  CAS  Google Scholar 

  59. Kitchener HC, Paraskevaidis E (2012) Patient’s preference: a sound basis for policy? BJOG 119(1):5–6

    PubMed  CAS  Google Scholar 

  60. Solomon D, Papillo JL, Davey DD, Atkison K, Bibbo M, Birdsong G, Bonfiglio T, Howell L, Jenkins E, Savaloja L, Wilbur D (2009) Cytopathology education and technology consortium. Statement on HPV DNA test utilization. Acta Cytol 53(3):247–248 (discussion 249–252)

    PubMed  Google Scholar 

  61. Jakobsson M, Gissler M, Paavonen J, Tapper AM (2009) Loop electrosurgical excision procedure and the risk for preterm birth. Obstet Gynecol 114(3):504–510

    PubMed  Google Scholar 

  62. Noehr B, Jensen A, Frederiksen K, Tabor A, Kjaer SK (2009) Loop electrosurgical excision of the cervix and subsequent risk for spontaneous preterm delivery: a population-based study of singleton deliveries during a 9-year period. Am J Obstet Gynecol 201(1):33.e1–33.e6

    Google Scholar 

  63. Bruinsma FJ, Quinn MA (2011) The risk of preterm birth following treatment for precancerous changes in the cervix: a systematic review and meta-analysis. BJOG 118(9):1031–1041

    PubMed  CAS  Google Scholar 

  64. Poon LC, Savvas M, Zamblera D, Skyfta E, Nicolaides KH (2012) Large loop excision of transformation zone and cervical length in the prediction of spontaneous preterm delivery. BJOG 119(6):692–698

    PubMed  CAS  Google Scholar 

  65. Stock SJ, Norman JE (2012) Treatments for precursors of cervical cancer and preterm labour. BJOG 119(6):647–649

    PubMed  CAS  Google Scholar 

  66. Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, Arbyn M, Prendiville W (2012) The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG 119(6):685–691

    PubMed  CAS  Google Scholar 

  67. Phadnis SV, Atilade A, Young MP, Evans H, Walker PG (2010) The volume perspective: a comparison of two excisional treatments for cervical intraepithelial neoplasia (laser versus LLETZ). BJOG 117(5):615–619

    PubMed  CAS  Google Scholar 

  68. Heinonen A, Gissler M, Riska A, Paavonen J, Tapper AM, Jakobsson M (2013) Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol 121:1063–1068

    PubMed  Google Scholar 

  69. Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, Saito H, Sobue T (2010) The Japanese guideline for cervical cancer screening. Jpn J Clin Oncol 40(6):485–502

    PubMed  Google Scholar 

  70. Department of Health and Ageing (2011) National cervical screening program. Canberra (Australia): Australian government. Available online: www.cancerscreening.gov.au/internet/screening/publishing.nsf/Content/cervical-about. Accessed 20 Aug 2013

  71. Canadian Task Force on Preventive Health Care (2013) Recommendations on screening for cervical cancer. CMAJ 185(1):35–45

    Google Scholar 

  72. Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF (2010) Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness. Obstet Gynecol 116(5):1158–1170

    PubMed  Google Scholar 

  73. Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA (2013) Hybrid capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 17(3):308–314 (in press)

    PubMed  Google Scholar 

  74. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U et al (2009) HPV PATRICIA study group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccines against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686):301–314

    PubMed  CAS  Google Scholar 

  75. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown, Koutsky LA, Tay EH, García P, Ault KA et al (2010) Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493. doi:10.1136/bmj.c3493

    PubMed  Google Scholar 

  76. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, Goldie SJ, Harper DM, Kinney W, Moscicki AB, Noller KL, Wheeler CM et al (2007) Gynecologic cancer advisory group, Garcia F. American cancer society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57(1):7–28

    PubMed  Google Scholar 

  77. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE (2011) The cost-effectiveness of male HPV vaccination in the United States. Vaccine 29(46):8443–8450

    PubMed  Google Scholar 

  78. Small SL, Patel DA (2012) Impact of HPV vaccine availability on uptake. J Nurse Practitioners 8(1):61–66

    Google Scholar 

  79. Sheinfeld Gorin SN, Glenn BA, Perkins RB (2011) The human papillomavirus (HPV) vaccine and cervical cancer: uptake and next steps. Adv Ther 28(8):615–639

    PubMed  Google Scholar 

  80. Mazzadi A, Paolino M, Arrossi S (2012) HPV vaccine acceptability and knowledge among gynecologists in Argentina. Salud Publica Mex 54(5):515–522

    PubMed  Google Scholar 

  81. Kane MA (2012) Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res (Phila) 5(1):24–29

    Google Scholar 

  82. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E (2013) Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs. 3 doses in young women: a randomized clinical trial. JAMA 309(17):1793–1802

    PubMed  CAS  Google Scholar 

  83. Kahn JA, Bernstein DI (2013) HPV vaccination: too soon for 2 doses? JAMA 309(17):1832–1834

    PubMed  CAS  Google Scholar 

  84. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Rådberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B et al (2009) Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 101:88–99

    PubMed  Google Scholar 

  85. de Kok IM, van Rosmalen J, Dillner J, Arbyn M, Sasieni P, Iftner T, van Ballegooijen M (2012) Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344:e670. doi:10.1136/bmj.e670

    PubMed  Google Scholar 

  86. Feldman S (2011) Making sense of the new cervical-cancer screening guidelines. N Engl J Med 365(23):2145–2147

    PubMed  CAS  Google Scholar 

  87. Nam EJ, Kim JW, Hong JW, Jang HS, Lee SY, Jang SY, Lee DW, Kim SW, Kim JH, Kim YT, Kim S, Kim JW (2008) Expression of the p16 and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. J Gynecol Oncol 19(3):162–168

    PubMed  Google Scholar 

  88. Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z (2011) IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 35:1638–1645

    PubMed  Google Scholar 

  89. Ovestad IT, Vennestrøm U, Andersen L, Gudlaugsson E, Munk AC, Malpica A, Feng W, Voorhorst F, Janssen EA, Baak JP (2011) Comparison of different commercial methods for HPV detection in follow-up cytology after ASCUS/LSIL, prediction of CIN2-3 in follow up biopsies and spontaneous regression of CIN2-3. Gynecol Oncol 123(2):278–283

    PubMed  Google Scholar 

  90. Gofrit ON, Shemer J, Leibovici D, Modan B, Shapira SC (2000) Quaternary prevention: a new look at an old challenge. Isr Med Assoc J 2(7):498–500

    PubMed  CAS  Google Scholar 

  91. CDC Atlanta—Sexually Transmitted Diseases Treatment Guidelines (2010) MMWR 59 (No RR-12):69–78

  92. Lee C, Mancuso V, Contant T, Jackson R, Smith-Mccune K (2003) Treatment of women with low-grade squamous intraepithelial lesions on cytologic evidence or biopsy result by board-certified gynecologists. Am J Obstet Gynecol 188(3):693–698

    PubMed  Google Scholar 

  93. Gross G (2001) Clinical aspects and therapy of anogenital warts and papillomavirus-associated lesions. Hautarzt 52(1):6–17

    PubMed  CAS  Google Scholar 

  94. Wolf R, Davidovici B (2010) Treatment of genital warts: facts and controversies. Clin Dermatol 28(5):546–548

    PubMed  Google Scholar 

  95. CDC: NNPTC: core training programs on STD Treatment Guidelines. Available at http://www.cdc.gov/STD/treatment

  96. Gérvas J, Starfield B, Heath I (2008) Is clinical prevention better than cure? Lancet 372:1997–1999

    PubMed  Google Scholar 

  97. Moynihan R, Doust J, Henry D (2012) Preventing overdiagnosis: how to stop harming the healthy. BMJ 344:e3502. doi:10.1136/bmj.e3502

    PubMed  Google Scholar 

  98. Moyer VA (2012) What we don’t know can hurt our patients: physician innumeracy and overuse of screening tests. Ann Intern Med 156:392–393

    PubMed  Google Scholar 

  99. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605–613

    PubMed  Google Scholar 

  100. Kahn JA, Slap GB, Bernstein DI, Kollar LM, Tissot AM, Hillard PA, Rosenthal SL (2005) Psychological, behavioural and interpersonal impact of human papillomavirus and Pap test results. J Womens Health 14(7):650–659

    Google Scholar 

  101. Arrossi S, Wiesner C (2012) The psychological and social costs of HPV testing in screening activities. HPV Today N 27, Nov

  102. Rosen NO, Knäuper B, Di Dio P, Morrison E, Tabing R, Feldstain A, Amsel R, Mayrand MH, Franco EL, Rosberger Z (2010) The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: a randomised controlled study. Psychol Health 25(6):651–668

    PubMed  Google Scholar 

  103. Kwan TT, Cheung AN, Lo SS, Lee PW, Tam KF, Chan KK, Ngan HY (2011) Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand 90(5):445–451

    PubMed  Google Scholar 

  104. Erickson BK, Alvarez RD, Huh WK (2013) Human papillomavirus: what every provider should know. Am J Obstet Gynecol 208(3):169–175

    PubMed  Google Scholar 

  105. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS (2009) Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 85(7):499–502

    PubMed  CAS  Google Scholar 

  106. Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 87(7):544–547

    PubMed  Google Scholar 

  107. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346:f2032. doi:10.1136/bmj.f2032

    PubMed  Google Scholar 

  108. Barton S, O’Mahony C (2013) HPV vaccination–reaping the rewards of the appliance of science. BMJ 346:f2184. doi:10.1136/bmj.f2184

    PubMed  Google Scholar 

  109. Kreimer AR, Chaturvedi AK (2011) HPV-associated oropharyngeal Cancers—are they preventable? Cancer Prev Res (Phila) 4(9):1346–1349

    Google Scholar 

  110. Jin XW, Lipold L, Sikon A, Rome E (2013) Human papillomavirus vaccine: safe, effective, underused. Cleve Clin J Med 80(1):49–60

    PubMed  Google Scholar 

Download references

Conflict of interest

The author states no funding and no conflict of interests.

Author information

Authors and Affiliations

  1. Gynecologic Oncology Unit, Department of Mother and Infant Sciences, University of Milan, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy

    Carlo A. Liverani

  2. Department of Obstetrics and Gynecology, University of Milan, Via Commenda, 12-20122, Milan, Italy

    Carlo A. Liverani

Authors
  1. Carlo A. Liverani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo A. Liverani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liverani, C.A. The four steps in the prevention of human papillomavirus-associated neoplasia. Arch Gynecol Obstet 288, 979–988 (2013). https://doi.org/10.1007/s00404-013-3011-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-013-3011-9

Keywords

Search

Navigation